| 44.2512 -2.079 (-4.49%) | 03-12 14:54 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 97.22 | 1-year : | 127.36 |
| Resists | First : | 83.24 | Second : | 109.04 |
| Pivot price | 50.49 |
|||
| Supports | First : | 41.5 | Second : | 34.52 |
| MAs | MA(5) : | 47.88 |
MA(20) : | 62.68 |
| MA(100) : | 87.96 |
MA(250) : | 58.64  |
|
| MACD | MACD : | -12.4 |
Signal : | -11.9 |
| %K %D | K(14,3) : | 11.8 |
D(3) : | 11.3 |
| RSI | RSI(14): 28.5 |
|||
| 52-week | High : | 118.83 | Low : | 20.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GRAL ] has closed above bottom band by 8.7%. Bollinger Bands are 54.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 48.96 - 49.43 | 49.43 - 49.71 |
| Low: | 44.58 - 45.17 | 45.17 - 45.53 |
| Close: | 45.65 - 46.62 | 46.62 - 47.2 |
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Thu, 12 Mar 2026
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
Mon, 09 Mar 2026
Joshua Ofman Sells 2,937 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat
Mon, 09 Mar 2026
Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 7,461 Shares of Stock - MarketBeat
Mon, 09 Mar 2026
Freidin, Grail CFO, sells $154k in GRAL stock - Investing.com Nigeria
Thu, 26 Feb 2026
Here’s What Analysts Are Saying About Grail Inc. (GRAL) - Yahoo Finance
Sat, 21 Feb 2026
GRAIL Stock: A Major Trial Disappointment (NASDAQ:GRAL) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 40 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 75.3 (%) |
| Shares Short | 5,460 (K) |
| Shares Short P.Month | 5,370 (K) |
| EPS | -11.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 63.91 |
| Profit Margin | -277.5 % |
| Operating Margin | -285.4 % |
| Return on Assets (ttm) | -11.4 % |
| Return on Equity (ttm) | -16.1 % |
| Qtrly Rev. Growth | 14 % |
| Gross Profit (p.s.) | 1.76 |
| Sales Per Share | 3.64 |
| EBITDA (p.s.) | -9.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -299 (M) |
| Levered Free Cash Flow | -106 (M) |
| PE Ratio | -4 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 12.16 |
| Price to Cash Flow | -5.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|